Malcolm R. Ranson
Manchester, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Journal: British journal of cancer
Published: May 31, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
Journal: Cancer chemotherapy and pharmacology
Published: April 26, 2018
EGFR T790M mutation testing within the osimertinib AURA Phase I study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 06, 2016
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 30, 2016
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.
Journal: Cancer chemotherapy and pharmacology
Published: January 04, 2016
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Journal: The New England journal of medicine
Published: April 30, 2015
A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 04, 2014
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 18, 2014
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Journal: Anti-cancer drugs
Published: March 19, 2014
Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system.
Journal: The Journal of molecular diagnostics : JMD
Published: March 11, 2013
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 13, 2012
Last Updated: 09/26/2026